Cargando…

Clinical and Genomic Epidemiology of mcr-9-Carrying Carbapenem-Resistant Enterobacterales Isolates in Metropolitan Atlanta, 2012 to 2017

Colistin is a last-resort antibiotic for multidrug-resistant Gram-negative infections. Recently, the ninth allele of the mobile colistin resistance (mcr) gene family, designated mcr-9, was reported. However, its clinical and public health significance remains unclear. We queried genomes of carbapene...

Descripción completa

Detalles Bibliográficos
Autores principales: Babiker, Ahmed, Bower, Chris, Lutgring, Joseph D., Petit, Robert A., Howard-Anderson, Jessica, Ansari, Uzma, McAllister, Gillian, Adamczyk, Michelle, Breaker, Erin, Satola, Sarah W., Jacob, Jesse T., Woodworth, Michael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431279/
https://www.ncbi.nlm.nih.gov/pubmed/35856667
http://dx.doi.org/10.1128/spectrum.02522-21
_version_ 1784780010007035904
author Babiker, Ahmed
Bower, Chris
Lutgring, Joseph D.
Petit, Robert A.
Howard-Anderson, Jessica
Ansari, Uzma
McAllister, Gillian
Adamczyk, Michelle
Breaker, Erin
Satola, Sarah W.
Jacob, Jesse T.
Woodworth, Michael H.
author_facet Babiker, Ahmed
Bower, Chris
Lutgring, Joseph D.
Petit, Robert A.
Howard-Anderson, Jessica
Ansari, Uzma
McAllister, Gillian
Adamczyk, Michelle
Breaker, Erin
Satola, Sarah W.
Jacob, Jesse T.
Woodworth, Michael H.
author_sort Babiker, Ahmed
collection PubMed
description Colistin is a last-resort antibiotic for multidrug-resistant Gram-negative infections. Recently, the ninth allele of the mobile colistin resistance (mcr) gene family, designated mcr-9, was reported. However, its clinical and public health significance remains unclear. We queried genomes of carbapenem-resistant Enterobacterales (CRE) for mcr-9 from a convenience sample of clinical isolates collected between 2012 and 2017 through the Georgia Emerging Infections Program, a population- and laboratory-based surveillance program. Isolates underwent phenotypic characterization and whole-genome sequencing. Phenotypic characteristics, genomic features, and clinical outcomes of mcr-9-positive and -negative CRE cases were then compared. Among 235 sequenced CRE genomes, 13 (6%) were found to harbor mcr-9, all of which were Enterobacter cloacae complex. The median MIC and rates of heteroresistance and inducible resistance to colistin were similar between mcr-9-positive and -negative isolates. However, rates of resistance were higher among mcr-9-positive isolates across most antibiotic classes. All cases had significant health care exposures. The 90-day mortality was similarly high in both mcr-9-positive (31%) and -negative (7%) CRE cases. Nucleotide identity and phylogenetic analysis did not reveal geotemporal clustering. mcr-9-positive isolates had a significantly higher number of median [range] antimicrobial resistance (AMR) genes (16 [4 to 22] versus 6 [2 to 15]; P < 0.001) than did mcr-9-negative isolates. Pangenome tests confirmed a significant association of mcr-9 detection with mobile genetic element and heavy metal resistance genes. Overall, the presence of mcr-9 was not associated with significant changes in colistin resistance or clinical outcomes, but continued genomic surveillance to monitor for emergence of AMR genes is warranted. IMPORTANCE Colistin is a last-resort antibiotic for multidrug-resistant Gram-negative infections. A recently described allele of the mobile colistin resistance (mcr) gene family, designated mcr-9, has been widely reported among Enterobacterales species. However, its clinical and public health significance remains unclear. We compared characteristics and outcomes of mcr-9-positive and -negative CRE cases. All cases were acquired in the health care setting and associated with a high rate of mortality. The presence of mcr-9 was not associated with significant changes in colistin resistance, heteroresistance, or inducible resistance but was associated with resistance to other antimicrobials and antimicrobial resistance (AMR), virulence, and heavy metal resistance (HMR) genes. Overall, the presence of mcr-9 was not associated with significant phenotypic changes or clinical outcomes. However, given the increase in AMR and HMR gene content and potential clinical impact, continued genomic surveillance of multidrug-resistant organisms to monitor for emergence of AMR genes is warranted.
format Online
Article
Text
id pubmed-9431279
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-94312792022-09-01 Clinical and Genomic Epidemiology of mcr-9-Carrying Carbapenem-Resistant Enterobacterales Isolates in Metropolitan Atlanta, 2012 to 2017 Babiker, Ahmed Bower, Chris Lutgring, Joseph D. Petit, Robert A. Howard-Anderson, Jessica Ansari, Uzma McAllister, Gillian Adamczyk, Michelle Breaker, Erin Satola, Sarah W. Jacob, Jesse T. Woodworth, Michael H. Microbiol Spectr Research Article Colistin is a last-resort antibiotic for multidrug-resistant Gram-negative infections. Recently, the ninth allele of the mobile colistin resistance (mcr) gene family, designated mcr-9, was reported. However, its clinical and public health significance remains unclear. We queried genomes of carbapenem-resistant Enterobacterales (CRE) for mcr-9 from a convenience sample of clinical isolates collected between 2012 and 2017 through the Georgia Emerging Infections Program, a population- and laboratory-based surveillance program. Isolates underwent phenotypic characterization and whole-genome sequencing. Phenotypic characteristics, genomic features, and clinical outcomes of mcr-9-positive and -negative CRE cases were then compared. Among 235 sequenced CRE genomes, 13 (6%) were found to harbor mcr-9, all of which were Enterobacter cloacae complex. The median MIC and rates of heteroresistance and inducible resistance to colistin were similar between mcr-9-positive and -negative isolates. However, rates of resistance were higher among mcr-9-positive isolates across most antibiotic classes. All cases had significant health care exposures. The 90-day mortality was similarly high in both mcr-9-positive (31%) and -negative (7%) CRE cases. Nucleotide identity and phylogenetic analysis did not reveal geotemporal clustering. mcr-9-positive isolates had a significantly higher number of median [range] antimicrobial resistance (AMR) genes (16 [4 to 22] versus 6 [2 to 15]; P < 0.001) than did mcr-9-negative isolates. Pangenome tests confirmed a significant association of mcr-9 detection with mobile genetic element and heavy metal resistance genes. Overall, the presence of mcr-9 was not associated with significant changes in colistin resistance or clinical outcomes, but continued genomic surveillance to monitor for emergence of AMR genes is warranted. IMPORTANCE Colistin is a last-resort antibiotic for multidrug-resistant Gram-negative infections. A recently described allele of the mobile colistin resistance (mcr) gene family, designated mcr-9, has been widely reported among Enterobacterales species. However, its clinical and public health significance remains unclear. We compared characteristics and outcomes of mcr-9-positive and -negative CRE cases. All cases were acquired in the health care setting and associated with a high rate of mortality. The presence of mcr-9 was not associated with significant changes in colistin resistance, heteroresistance, or inducible resistance but was associated with resistance to other antimicrobials and antimicrobial resistance (AMR), virulence, and heavy metal resistance (HMR) genes. Overall, the presence of mcr-9 was not associated with significant phenotypic changes or clinical outcomes. However, given the increase in AMR and HMR gene content and potential clinical impact, continued genomic surveillance of multidrug-resistant organisms to monitor for emergence of AMR genes is warranted. American Society for Microbiology 2022-07-20 /pmc/articles/PMC9431279/ /pubmed/35856667 http://dx.doi.org/10.1128/spectrum.02522-21 Text en Copyright © 2022 Babiker et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Babiker, Ahmed
Bower, Chris
Lutgring, Joseph D.
Petit, Robert A.
Howard-Anderson, Jessica
Ansari, Uzma
McAllister, Gillian
Adamczyk, Michelle
Breaker, Erin
Satola, Sarah W.
Jacob, Jesse T.
Woodworth, Michael H.
Clinical and Genomic Epidemiology of mcr-9-Carrying Carbapenem-Resistant Enterobacterales Isolates in Metropolitan Atlanta, 2012 to 2017
title Clinical and Genomic Epidemiology of mcr-9-Carrying Carbapenem-Resistant Enterobacterales Isolates in Metropolitan Atlanta, 2012 to 2017
title_full Clinical and Genomic Epidemiology of mcr-9-Carrying Carbapenem-Resistant Enterobacterales Isolates in Metropolitan Atlanta, 2012 to 2017
title_fullStr Clinical and Genomic Epidemiology of mcr-9-Carrying Carbapenem-Resistant Enterobacterales Isolates in Metropolitan Atlanta, 2012 to 2017
title_full_unstemmed Clinical and Genomic Epidemiology of mcr-9-Carrying Carbapenem-Resistant Enterobacterales Isolates in Metropolitan Atlanta, 2012 to 2017
title_short Clinical and Genomic Epidemiology of mcr-9-Carrying Carbapenem-Resistant Enterobacterales Isolates in Metropolitan Atlanta, 2012 to 2017
title_sort clinical and genomic epidemiology of mcr-9-carrying carbapenem-resistant enterobacterales isolates in metropolitan atlanta, 2012 to 2017
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431279/
https://www.ncbi.nlm.nih.gov/pubmed/35856667
http://dx.doi.org/10.1128/spectrum.02522-21
work_keys_str_mv AT babikerahmed clinicalandgenomicepidemiologyofmcr9carryingcarbapenemresistantenterobacteralesisolatesinmetropolitanatlanta2012to2017
AT bowerchris clinicalandgenomicepidemiologyofmcr9carryingcarbapenemresistantenterobacteralesisolatesinmetropolitanatlanta2012to2017
AT lutgringjosephd clinicalandgenomicepidemiologyofmcr9carryingcarbapenemresistantenterobacteralesisolatesinmetropolitanatlanta2012to2017
AT petitroberta clinicalandgenomicepidemiologyofmcr9carryingcarbapenemresistantenterobacteralesisolatesinmetropolitanatlanta2012to2017
AT howardandersonjessica clinicalandgenomicepidemiologyofmcr9carryingcarbapenemresistantenterobacteralesisolatesinmetropolitanatlanta2012to2017
AT ansariuzma clinicalandgenomicepidemiologyofmcr9carryingcarbapenemresistantenterobacteralesisolatesinmetropolitanatlanta2012to2017
AT mcallistergillian clinicalandgenomicepidemiologyofmcr9carryingcarbapenemresistantenterobacteralesisolatesinmetropolitanatlanta2012to2017
AT adamczykmichelle clinicalandgenomicepidemiologyofmcr9carryingcarbapenemresistantenterobacteralesisolatesinmetropolitanatlanta2012to2017
AT breakererin clinicalandgenomicepidemiologyofmcr9carryingcarbapenemresistantenterobacteralesisolatesinmetropolitanatlanta2012to2017
AT satolasarahw clinicalandgenomicepidemiologyofmcr9carryingcarbapenemresistantenterobacteralesisolatesinmetropolitanatlanta2012to2017
AT jacobjesset clinicalandgenomicepidemiologyofmcr9carryingcarbapenemresistantenterobacteralesisolatesinmetropolitanatlanta2012to2017
AT woodworthmichaelh clinicalandgenomicepidemiologyofmcr9carryingcarbapenemresistantenterobacteralesisolatesinmetropolitanatlanta2012to2017